Featured Articles

PharmaMar forays into an exclusive licensing agreement with Seattle Genetics ensuring access to certain PharmaMar proprietary molecules for the development and commercialization of…
Read More...

Amgen asserted that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration will assess the data supporting the BLINCYTO supplemental Biologics License…
Read More...

Charles River Laboratories International declared that it has ventured into a definitive agreement to obtain MPI Research for $800 million in cash. James C. Foster, Chairman and…
Read More...

Degenerative disc disease has long been considered an inseparable part of aging but new breakthrough research from SpinalCyte suggests a new cell-based therapy could provide a cure for…
Read More...

Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...

In a bid to treat metastatic radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), Exelixis declared results from a Phase 2 Investigator-sponsored trial of cabozantinib.…
Read More...

Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...

European Commission extends approval to Celltrion's Herzuma for treatment of patients with early breast Cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have…
Read More...

Teva Pharmaceutical announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of…
Read More...

ProBioGen announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial…
Read More...

Results from the Phase 1/2 trial (NEO1) and its ongoing extension study (NEO-EXT) show consistent safety data for Sanofi’s investigational avalglucosidase alfa (neoGAA) in patients with…
Read More...

Bavarian Nordic A/S announced positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study achieved both of its primary…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat…
Read More...

PharmaJet announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis needle-free…
Read More...

AstraZeneca announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial…
Read More...

Acesion Pharma announces that it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a…
Read More...

GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero for the…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a…
Read More...

Novo Nordisk announced that Rebinyn, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B. Rebinyn is an…
Read More...